Neuphoria Therapeutics Inc. (NEUP) shareholders
Close on Nov 12, 2026Market cap $77.56KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lynx1 Capital Management LP Joint filing with Weston Nichols (16.30%) | 875,328 | 16.30% | 13D (active) amendment | Dec 2, 2025 |
| Weston Nichols Joint filing with Lynx1 Capital Management LP (16.30%) | 875,328 | 16.30% | 13D (active) amendment | Dec 26, 2025 |
| AdvisorShares Trust | 312,895 | 5.78% | 13G (passive) | Sep 30, 2026 |
| Shay Capital LLC Joint filing with Shay Capital Holdings LLC (7.30%) | 171,629 | 7.30% | 13G (passive) | Oct 24, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NEUP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 875,328 | 16.18% | $3.83M | – | 0.44% |
| AdvisorShares Investments LLC | 252,909 | 4.67% | $1.11M | +97,542 | 0.13% |
| Vanguard Capital Management LLC | 173,488 | 3.21% | $758.14K | +74,972 | 0.00% |
| Shay Capital LLC | 155,822 | 2.88% | $680.94K | +4,812 | 0.04% |
| Balyasny Asset Management L.P. | 142,228 | 2.63% | $621.54K | +45 | 0.00% |
| Citadel Advisors LLC | 72,559 | 1.34% | $317.08K | +53,228 | 0.00% |
| Geode Capital Management, LLC | 49,516 | 0.92% | $216.38K | −2,491 | 0.00% |
| Ikarian Capital, LLC | 47,443 | 0.88% | $207.33K | – | 0.02% |
| Vanguard Fiduciary Trust Co | 33,806 | 0.62% | $147.73K | +217 | 0.00% |
| ADAR1 Capital Management, LLC | 30,000 | 0.55% | $131.10K | – | 0.01% |
| FNY Investment Advisers, LLC | 26,500 | 0.49% | $115.00K | – | 0.04% |
| Renaissance Technologies LLC | 25,500 | 0.47% | $111.44K | New | 0.00% |
| XTX Topco Ltd | 23,089 | 0.43% | $100.90K | New | 0.00% |
| Hrt Financial LP | 22,865 | 0.42% | $99.00K | New | 0.00% |
| Jane Street Group, LLC | 14,903 | 0.28% | $65.13K | New | 0.00% |
| Boothbay Fund Management, LLC | 14,000 | 0.26% | $61.18K | – | 0.00% |
| Commonwealth Equity Services, LLC | 11,222 | 0.21% | $49.04K | – | 0.00% |
| Northern Trust Corp | 10,610 | 0.20% | $46.37K | New | 0.00% |
| Merck & Co., Inc. | 10,027 | 0.19% | $43.82K | – | 0.01% |
| UBS Group AG | 2,117 | 0.04% | $9.25K | −199 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 22 | 2M | 36.8% | 6 / 6 | 2 / 3 | 0M | 0M |
| Q1 2026 | 19 | 2M | 32.5% | 6 / 5 | 1 / 7 | 0M | 0M |
| Q4 2025 | 21 | 1M | 27.1% | 9 / 9 | 1 / 3 | 1M | 0M |
| Q3 2025 | 15 | 0M | 3.6% | 9 / 2 | 1 / 3 | 0M | 0M |
| Q2 2025 | 9 | 0M | 3.3% | 2 / 1 | 2 / 0 | 0M | 0M |
| Q1 2025 | 7 | 0M | 3.0% | 3 / 0 | 1 / 4 | 0M | 0M |
| Q4 2024 | 8 | 0M | 1.5% | 8 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
7 funds held NEUP in Q2 2026, 91% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NEUP | Value | % of fund | As of |
|---|---|---|---|---|---|
| AdvisorShares Psychedelics ETF | 252,909 | 4.67% | $1.11M | 2.49% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 110,171 | 2.04% | $481.45K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 63,317 | 1.17% | $276.70K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 31,546 | 0.58% | $167.51K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 8,036 | 0.15% | $42.67K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 2,427 | 0.04% | $12.89K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,001 | 0.04% | $10.63K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Spyros Papapetropoulos | President and CEO, Director | 5,999,940 | 110.88% | Sep 2, 2025 |
| Peter Miles Winston Davies | Director | 269,984 | 4.99% | Jan 21, 2026 |
| Jane Ryan | Director | – | – | Jan 21, 2026 |
| Alan Fisher | Director | 100,000 | 1.85% | Jan 21, 2026 |
| David Ian Wilson | Director | 251,939 | 4.66% | Jan 21, 2026 |
| Weston Nichols | 10% owner | – | – | Oct 23, 2025 |
| Capital Management LP Lynx1 | 10% owner | 236,218 | 4.37% | Oct 23, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Capital Management LP Lynx1 10% owner | Oct 21, 2025 | Buy | +639,110 | $5.14 | $3.29M | 875,328 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Neuphoria Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,536 shares on Aug 28, 2026 over the last 90 days.
See a number that looks wrong?